{Reference Type}: Journal Article
{Title}: Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma.
{Author}: Gogineni E;Sells BE;Dibs K;Jhawar SR;Haring CT;Limbach AL;Konieczkowski DJ;Ma SJ;Zhu S;Baliga S;Mitchell DL;Grecula JC;Bonomi M;Bhateja P;Old MO;Seim NB;Kang SY;Rocco JW;Chakravarti A;Blakaj DM;Gamez ME;
{Journal}: Cancers (Basel)
{Volume}: 16
{Issue}: 6
{Year}: 2024 Mar 19
{Factor}: 6.575
{DOI}: 10.3390/cancers16061204
{Abstract}: <B>BACKGROUND: </B>Salivary duct carcinomas (SDC) are a rare and aggressive subtype of salivary gland neoplasm. They can present with distinct immunoprofiles, such as androgen receptor (AR) and HER-2/Neu-positivity. To date, no consensus exists on how to best manage this entity.<BR><B>METHODS: </B>All patients diagnosed with nonmetastatic AR+ SDC of the parotid from 2013 to 2019 treated with curative intent were included. Immunologic tumor profiling was conducted using 24 distinct markers. Kaplan-Meier analyses were used to estimate locoregional recurrence (LRR), distant control, and overall survival (OS).<BR><B>RESULTS: </B>Fifteen patients were included. Nine (60%) patients presented with T4 disease and eight (53%) had positive ipsilateral cervical lymphadenopathy. Ten (67%) patients underwent trimodality therapy, including surgery followed by adjuvant radiation and concurrent systemic therapy. The median follow-up was 5.5 years (interquartile range, 4.8-6.1). The estimated 5-year rates of LRR, distant progression, and OS were 6%, 13%, and 87%, respectively.<BR><B>CONCLUSIONS: </B>Despite only including AR+ SDC of the parotid, immunoprofiles, such as expression of HER-2, were highly variable, highlighting the potential to tailor systemic regimens based on individual histologic profiles in the future. Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors. Molecularly informed treatment approaches, including the potential use of AR- and HER-2/Neu-directed therapies upfront in the definitive setting, may hold future promise to further improve outcomes for these patients.